Myotilin is a muscle-specific Z-disc protein with putative roles in myofibril assembly and structural upkeep of the sarcomere. Several myotilin point mutations have been described in patients with Limb-Girdle Muscular Dystrophy Type 1A (LGMD1A), myofibrillar myopathy (MFM), and spheroid body myopathy (SBM), three similar adultonset, progressive, and autosomal dominant muscular dystrophies. To further investigate myotilin's role in the pathogenesis of these muscle diseases, we have characterized three independent lines of transgenic mice expressing mutant (T57I) myotilin under the control of the human skeletal actin (HSA) promoter. Like LGMD1A and MFM patients, these mice develop progressive myofibrillar pathology that includes Z-disc streaming, excess myofibrillar vacuolization, and plaque-like myofibrillar aggregation. These aggregates become progressively larger and more numerous with age. We show that the mutant myotilin protein properly localizes to the Z-disc, and also heavily populates the aggregates, along with several other Z-disc associated proteins. Whole muscle physiological analysis reveals that the extensor digitorum longus (EDL) muscle of transgenic mice exhibits significantly reduced maximum specific isometric force compared to littermate controls. Intriguingly, the soleus and diaphragm muscles are spared of any abnormal myopathology and show no reductions in maximum specific force. These data provide evidence that myotilin mutations promote aggregate-dependent contractile dysfunction. In sum, we have established a promising patho-physiological mouse model that unifies the phenotypes of LGMD1A, MFM, and SBM.
INTRODUCTION
The muscular dystrophies comprise a large number of clinically and molecularly heterogeneous myopathic diseases, characterized by progression in muscle weakness and histological evidence of muscle fiber degeneration and regeneration. A subset, the limbgirdle muscular dystrophies (LGMDs), is characterized by initial or predominant weakness of the shoulder and hip girdle muscles (1) . The similarity in clinical presentation of LGMD and other muscle diseases often complicates diagnosis.
LGMDs exist in both autosomal dominant forms (type I, LGMD1A-G) and recessive forms (type II, LGMD2A-J). Given the extensive phenotypic heterogeneity of LGMD, sub-types are positionally or molecularly defined; 13 independent gene defects resulting in LGMD have been reported to date (2) .
The subject of this report, LGMD1A (MIM 604103), is an autosomal dominant muscle disease with a mean age at onset of 27 years, characterized by initial weakness of proximal girdle muscles (3) . Muscular symptoms progress in both severity and distribution, as more distal limb muscles also become affected. Biopsied skeletal muscle shows several signs of myopathy -degeneration of myofibers, fiber splitting, variations in fiber size, fibrosis, and centrally located myonuclei (4) . Ultrastructural analysis reveals a large number of autophagic vacuoles and extensive Z-disc streaming.
characterized pathologically by dense patches of SBM-like sarcomeric disarray and aggregation. Genetic studies of MFM have highlighted the importance of additional Zdisc proteins in sarcomere function. Mutation of the myotilin-binding protein, FLNC, causes an MFM (MIM#609524) characterized by intrasarcoplasmic aggregates similar to those seen in myotilin-associated MFM (16) . MFM is also caused by mutations in the Zdisc proteins, ZASP (z-band alternatively spliced PDZ-containing protein; MIM#609542) (17) , and desmin (MIM#601419) (18) (19) (20) , and the chaperone protein, αB-crystallin (CRYAB, MIM#608810) (21, 22) . Despite recent genetic triumphs, LGMD1A, myotilinrelated MFM, and SBM, collectively termed the myotilinopathies, remain clinically illdefined muscle disorders with considerable inter-and intra-familial variation.
A thorough molecular dissection of myotilinopathy disease etiology has largely been limited by the availability of human tissue and the lack of an experimental model system. To address these needs, we have created a transgenic mouse model by expressing the human myotilin cDNA bearing the T57I mutation on a wild-type murine myotilin background. These transgenic mice reproduce many of the symptoms and pathology associated with the myotilinopathies-Z-disc streaming, myofibrillar aggregation, and muscle weakness. This mouse model not only unifies the diverse phenotypes of the human myotilinopathies, but also promises to be a key resource for understanding myotilin function, unraveling LGMD1A pathogenesis, and investigating possible therapeutics.
RESULTS

Generation of myotilin transgenic mice
We modeled the autosomal dominant disease LGMD1A by co-expressing a mutant human myotilin transgene in the presence of normal levels of endogenous wildtype murine myotilin. The mutant transgene contains the human myotilin cDNA with the
LGMD1A T57I point mutation, cloned downstream of the skeletal-muscle specific human skeletal actin (HSA) promoter (Fig. 1) . We chose to use the human cDNA because there are sequence differences between murine and human myotilin near the mutation site, and we wanted to avoid the possibility that these differences would alter the effects of the human mutation. Because myotilin antibodies recognizes both human and murine proteins, we incorporated a c-myc epitope tag at the N-terminus of the human transgene product, thus enabling transgene-specific quantification and localization.
Transgenes were genotyped by PCR amplification (Fig. 1) , and a single site of insertion was verified by Southern blot (data not shown). Transgene expression and transgeneassociated pathology were similar in three distinct T57I mutant myotilin lines. We chose to thoroughly characterize line 71, Tg(HSA-MYOT)71Mah, hereafter referred to as TgT57I. We also generated a line of mice expressing a similar transgene containing the wild-type human myotilin cDNA, Tg(HSA-MYOT)12Mah, hereafter referred to as TgWT. These two transgenic constructs differ only by the single base pair that causes the T57I amino acid substitution. Transgenic mice were obtained at the expected Mendelian ratio, and neither TgT57I nor the TgWT mice displayed gross abnormalities or reduced survival. RT-PCR analysis shows that transgene expression is limited to skeletal muscle in both TgT57I (Fig. 1) and TgWT mice (data not shown). Western blotting with a cby guest on September 23, 2016 http://hmg.oxfordjournals.org/ Downloaded from myc antibody specific to the transgene product shows that the expected 57 kD TgT57I protein is appropriately expressed in multiple muscles (Fig. 1) . This c-myc antibody also allows a direct comparison of transgene expression levels: TgWT mice express their transgene product at 2-to 3-fold higher levels than do TgT57I mice, as determined by analysis of soluble fractions of quadriceps muscle lysates (Fig. 1) . The abundance of TgWT expression is further confirmed using an antibody raised to a peptide that is identical in human and murine myotilin (Fig. 1) . Scanning densitometry was used to determine that TgWT levels are 7.7-fold higher than endogenous levels, while TgT57I levels are 2.6-fold higher than endogenous levels. Immunostaining of frozen muscle cross-sections shows that transgene expression is uniform across myofibers within a given muscle group and also similar between slow type I and fast type II fibers (Fig. 1 ).
There is no overt toxicity associated with overexpression of the human Nterminally epitope-tagged myotilin transgene product (TgWT) in mouse skeletal muscle, even at two years of age. While we do observe age-related pathology common to transgene-negative littermate controls (i.e., tubular aggregates and rimmed vacuoles), minimal transgene-specific pathology is observed. 18-month TgWT tricep, quadricep, EDL, and soleus muscle histology is comparable to 12-month control muscle (Fig. 2) .
We observe small eosinophilic aggregates beneath the sarcolemma in quadriceps and triceps muscles of older TgWT mice as result of significant myotilin overexpression.
Because the TgWT protein is expressed at several-fold higher levels than the TgT57I product, any pathology in TgT57I mice must be caused solely by the T57I point mutation.
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TgT57I mice develop progressive myofibrillar pathology
Expression of T57I mutant myotilin results in a myofibrillar muscle pathology remarkably similar to that seen in the human myotilinopathies. TgT57I mice develop dense and irregular myofibrillar aggregates (Fig. 2) . A survey of muscles from a 12-month old TgT57I mouse shows that the myofibrillar aggregates are prevalent in two proximal muscle groups, the quadriceps and triceps, and also in the EDL muscle (Fig. 2) .
Fibrosis, adipose infiltration, and increased tubular aggregation also occur in older TgT57I muscle (Fig. 2 ).
Muscle pathology in the TgT57I mouse is progressive, with both the size and number of aggregates increasing with age. At two weeks of age, aggregates are small, focal points, that subsequently expand up to 40 μm in diameter, often occupying the entire cross-sectional areas of myofibers in older mice (Fig. 3) . The number of affected fibers also increases with age: survey of at least 800 myofibers from the quadriceps shows that the proportion containing aggregates increases from 11.7% at 6 months to 17.8% at 12 months. During the same time period, the number of affected fibers in the triceps muscle increases from 11.6% to 18.2%. Different muscle groups show different levels of myopathic involvement (Table   1) . Quadriceps, triceps, and hamstring muscles exhibit a higher proportion of myofibers with aggregates than EDL, gastrocnemius, abdominal wall, and tibialis muscles.
Interestingly, the diaphragm, soleus, bicep, and ulnar muscles show no evidence of myofibrillar aggregation. This selectivity of muscle group involvement is also seen in human patients: magnetic resonance imaging of myotilin-related MFM patients has revealed selective muscle wasting in the leg (15) . The three most severely affected muscles in TgT57I mice are upper forelimb and hindlimb muscles -precisely the same muscle groups that show initial weakness in LGMD1A patients.
Ultrastructural analysis of TgT57I muscle
TgT57I muscle recapitulates the ultrastructural defects observed in human myotilinopathy patients. Broadening of isolated Z-discs is observed in both single
LGMD1A sarcomeres and in TgT57I muscle (Fig. 4) . Disrupted Z-discs may subsequently merge into streaming bodies involving multiple Z-discs. Z-disc streaming in TgT57I mice is indistinguishable from the pathology seen in human LGMD1A patients (Fig. 4) . TgT57I muscle also develops striking patches of sarcomeric deterioration and aggregation. These myofibrillar aggregates are irregular, amorphous, and devoid of any peripheral or internal membranous material. Myofibrillar aggregates are often associated with autophagic vesicles (Fig. 4) , a vacuolar pathology that is prevalent in LGMD1A muscle. Myofibrillar aggregates are also sometimes associated with tubular aggregates, a non-specific pathology observed in older inbred male mice (23) . These tubular aggregates are more prevalent in TgT57I mice than male littermate controls (data not shown). Tubular aggregates have been reported to be associated with the intrasarcoplasmic aggregates in SBM patient muscle (24) . Centrally located nuclei are observed in TgT57I thin sections, but not regularly. Sarcolemmal, mitochondrial, and nuclear structures all appear normal by electron microscopy. TgWT muscle exhibits normal sarcomeric ultrastructure, however, small aggregates can be found beneath the sarcolemma in older mice (Fig. 4) . These sub-sarcolemmal aggregates are commonly less than 5 um in diameter and contain embedded, often fragmented, vesicles. The appearance of these aggregates contrasts sharply with that of larger myofibrillar aggregates in TgT57I mice that are devoid of any membranous deposits. Ultrastructural analysis of TgT57I muscle further highlights the largely myofibrillar pathology that is common to the human myotilinopathies.
Mutant myotilin and Z-disc proteins localize to the aggregates
The myofibrillar aggregates in TgT57I muscle harbor several Z-disc proteins, including the mutant transgene product (Fig.5) . Immunostaining for the c-myc epitope tag allows for specific localization of the transgene products. Both the TgWT and TgT57I products localize normally to the Z-disc, but the T57I mutant protein is also found in the myofibrillar aggregates (Fig. 5) . Overexpression of wild-type myotilin also drives sub-sarcolemmal accumulation. We investigated the localization of several other Z-disc-associated proteins. While ACTN2, FLNC, and desmin all localize to the Z-disc in muscles from TgT57I, TgWT, and control littermates, these proteins also localize heavily to the aggregates in TgT57I muscle. Slight accumulation of FLNC and desmin can be observed in TgWT muscle. Sarcomeric proteins titin and myosin localize to the aggregates as well, however vinculin does not (data not shown). In addition, the aggregates contain ubiquitinated protein (Fig. 5) . Similar patterns of ectopic expression have been reported in MFM and SBM muscle (14, 15, 25, 26) . In order to quantitate the level of accumulation of proteins found in the aggregates, we conducted immunoblot analysis of the insoluble fractions of muscle lysates from 12-month old mice. The aggregates are not represented in the soluble fractions shown in Fig. 1 . We specifically examined the soleus, which is spared, and the quadriceps muscles, which are severely affected. Soleus muscle shows minimal accumulation of the TgT57I product, while this protein is present at high levels in the quadriceps (Fig. 6 ). This is most likely a reflection of the difference in aggregate burden between the two muscles. FLNC and desmin levels are increased in the quadriceps, but not in the soleus, while ACTN2 levels are unchanged (Fig. 6 ). These differences reflect the levels of these proteins in the myofibrillar aggregates (Fig. 5) .
Maintenance of sarcolemmal integrity in myotilin transgenic mice
Vital staining with Evans blue dye (EBD) was used to evaluate plasma membrane permeability in myotilin transgenic mice. EBD is a small molecular weight tracer that binds to serum albumin; the EBD-albumin complex can easily pass into the sarcoplasm of myofibers with a damaged sarcolemma. Macroscopic evaluation of forelimbs and hindlimbs showed little EBD uptake in either 12-month old TgWT mice and control littermate, or in 9-month old TgT57I mice ( (27, 28) . These data indicate that the sub-sarcolemmal miniaggregates do not disrupt sarcolemmal integrity in TgWT muscle. Moreover, maintenance of sarcolemmal integrity in TgT57I muscle further distinguishes this mouse model from others that have been associated with membrane defects.
TgT57I mice exhibit contractile dysfunction in selective muscle groups
Significant physiological dysfunction was detected in whole, intact EDL muscles of TgT57I mice. TgT57I EDL muscle mass is reduced by 33% as compared to littermate controls (8.8 mg in TgT57I, 13.2 mg in controls, Fig. 8 EDL and diaphragm muscles from TgT57I mice are less vulnerable to contraction-induced injury than those from littermate controls. Susceptibility to injury is measured by stimulating a muscle to contract while simultaneously stretching it.
Maximum isometric force generation before and after the stretch is used to calculate a force deficit-muscles susceptible to damage will show a large force deficit. After a lengthening contraction protocol, EDL and diaphragm of TgT57I show less of a force deficit than muscles from littermate controls (Fig 8) . Lengthening contraction-induced force deficit values for TgWT EDL and soleus are statistically indistinguishable from littermate controls.
DISCUSSION
We have generated a transgenic mouse model that successfully recapitulates the pathological features of human myotilinopathies. The myotilinopathies, including
LGMD1A, MFM, and SBM, comprise an autosomal dominant class of muscle diseases, all caused by missense mutations in exon 2 of the myotilin gene. Despite the proximity and similarity of these mutations, the reported clinical features of LGMD1A, MFM, and SBM are somewhat divergent.
LGMD1A patients typically present with proximal muscle weakness, while distal muscle weakness is common in myotilin-related MFM (14) . The defining features of MFM and SBM are dense sarcoplasmic bodies, yet this pathology has not yet been reported in LGMD1A. However, the transgenic mouse model we have presented here unites these disparate phenotypes. The TgT57I mouse displays expansive myofibrillar aggregation very similar to the hallmark pathologies observed in MFM and SBM. At the same time, these mice display the abundant autophagic vesicles and Z-disc streaming that are characteristic of LGMD1A patients. This strongly suggests that the T57I myotilin mutation can induce all of the skeletal muscle pathologies observed in the human myotilinopathies, and raises the possibility that variations in the presentation of human patients are the result of modifier loci.
The myotilin T57I mutation promotes myofibrillar aggregation
The myofibrillar aggregates and Z-disc streaming found in our TgT57I mouse model reflect dramatic disruptions in muscle structure-it is surprising that such profound changes can arise from a seemingly conservative amino acid replacement in the myotilin protein. We propose two potential mechanisms: first, mutant myotilin could act directly to nucleate protein aggregates, and second, mutant myotilin could act indirectly by disrupting actin tethering at the Z-disc. proteins at the Z-disc may well mediate rapid association of proteins to promote Z-disc assembly. In the TgT57I mouse, it does not appear that Z-disc assembly is adversely affected, since aggregates are not observed in younger mice. Direct nucleation mechanisms such as these imply that the missense substitution in the N-terminal domain of myotilin is able to alter the binding properties of the C-terminal IgL domains.
Alternatively, myotilin mutations could indirectly lead to myofibrillar aggregation by destabilizing actin tethering at the Z-disc. The myofiber Z-disc houses a dense network of proteins that anchors actin filaments, thus facilitating the production and transmission of actin-myosin-initiated force. The chief F-actin cross-linking protein of the Z-disc is α-actinin, which interacts with myotilin (8) and a number of other Z-disc proteins, including nebulin (31), the α-actinin-associated LIM-protein (ALP) (32), the calsarcins (33), titin (34, 35) , ZASP (36) , and myopalladin (30) . Myotilin also associates directly with F-actin, thereby bundling and stabilizing actin filaments. Through possible combinatorial interactions with additional actin and alpha-actinin binding proteins that localize to the Z-disc (i.e., ACTN2, FLNC, calsarcin-2), myotilin may be even more intimately involved with actin stabilization and Z-disc function. Clearly, myotilin mutations could easily interfere with the total actin-tethering capacity of the Z-disc. This indirect mechanism of aggregate formation is strongly supported by the pathology in TgT57I muscle. The spectrum of Z-disc pathology, from discrete broadening to streaming to myofibrillar aggregation, suggests that initial Z-disc destabilization leads to the stochastic increase in protein aggregation. In vitro work in COS-7 cells suggests that the T57I mutation has no effect on actin binding or bundling, nor does it induce formation of aggregates (12) . The dramatic effect of this T57I mutation in live, contracting murine muscle suggests that additional functional testing of mutant myotilin is required.
TgT57I muscle pathophysiology is muscle group dependent
In the TgT57I mouse, muscle groups with differences in fiber composition displayed significant variation in pathological involvement. The skeletal muscles of adult wild-type mice are composed of three different fiber types, one slow type I fiber type and two fast type II fiber types, IIA and IIB, also termed slow-oxidative (SO), fast oxidativeglycolytic (FOG) and fast glycolytic (FG) fibers (37) . The three fiber types have unique physiologic characteristics and genomic expression profiles (37, 38) . The EDL muscle of the mouse is composed completely of fast fibers with ~87% fast type IIB fibers (39) .
Gastrocnemius also contains predominantly type IIB fibers (79%) (39 A major difference between fast type II and slow type I fibers and muscles is their susceptibility to contraction-induced injury. The fast type II fibers, and muscles largely composed of these fibers, display a three-to four-fold greater force deficit for a given strain, or for a given amount of work done to stretch a fiber (46, 47) . Surprisingly, the EDL and diaphragm muscles in the TgT57I mice do not display the high force deficits expected. Similar observations of low values for maximum force and for force deficits have been made in fatigued muscles and in the muscles of desmin-deficient mice (48, 49) .
This resistance to contraction-induced injury may be secondary to the reduced forcegenerating capacity of the EDL muscle. This interpretation is supported further by the data on the soleus muscles of TgT57I mice compared with littermate controls, which did not differ in either force-generating capacity or in susceptibility to contraction-induced injury. The magnitude of the force deficit correlates highly with the work required to stretch the muscle, which is the product of the displacement and the average force developed by the muscle during the strain (47, 50, 51) . Consequently, the EDL muscle of 
The TgT57I mouse complements current MFM models
Mutations in multiple genes other than myotilin have been shown to cause MFM-mouse models incorporating several of these genes have been reported. Adult desmin knock-out mice show signs of muscle degeneration, Z-disc streaming, and myofibril misalignment, but myofibrillar aggregation does not occur (54, 55) . In contrast to normal TgT57I diaphragm and soleus muscles, desmin-null diaphragm exhibits increased degeneration, and desmin-null soleus muscle generates 90% less maximum isometric force (54) . These pathophysiological differences can be explained both by desmin's additional role at myofiber costameres, structures that connect Z-discs to the sarcolemma, and by the approach of targeted inactivation of desmin, rather than transgenic expression. Indeed, transgenic expression of the MFM desmin allele, D7-des (deletion of 7 amino acids, 173-179) causes intrasarcoplasmic aggregation in cardiac myocytes. Cardiac-restricted expression by the α-myosin heavy chain promoter prevents the opportunity to study skeletal myopathy in this model (56) .
Targeted inactivation of another MFM gene, αB-crystallin (CRYAB), causes nonspecific histological features of muscular dystrophy and small patches of amorphous granules in older mice, but no significant myofilbrillar aggregation (57) . In the same way as the transgenic desmin allele, cardiac-restricted transgenic expression of the CRYAB R120G MFM mutation causes eosinophilic aggregation in cardiac myocytes (58) .
Targeted inactivation of cypher, the murine ortholog of ZASP, causes perinatal lethality, right and left ventricular dilation, and disorganization of skeletal muscle Z-discs, and no aggregation is observed (59) . The desmin, CRYAB, and ZASP mouse mutants have proven very successful in the study of cardiac failure associated with MFM. The transgenic myotilin T57I mouse, however, best captures the skeletal muscle phenotype of MFM. The desmin/CRYAB and myotilin transgenic mouse models complement each other well in the effort to identify the causes and functional impacts of myofibrillar aggregation in cardiac and skeletal muscle.
Therapeutic potential of myotilin transgenic mouse models
Analysis of our TgWT mouse demonstrates that in vivo expression of high levels of wild-type myotilin protein results in small sub-sarcolemmal aggregates and slight accumulation of FLNC and desmin in TgWT mice (Figs. 5,6 ). However, these minor abnormalities do not induce any changes in sarcolemmal integrity (Fig. 7) or physiologic function of the muscle (Fig. 8) . The lack of toxicity of high levels of myotilin protein raises the possibility that myotilin overexpression could be used therapeutically to treat muscle diseases caused by sarcomeric dysfunction, especially those characterized by Histology. Mice were transcardially perfusion-fixed with 4% paraformaldehyde in PBS.
Dissected muscle was then fixed at least overnight at room temperature, also in 4% paraformaldehyde in PBS. Tissue was then dehydrated in 70% ethanol and processed via manufacturer's instructions in an automatic processor (Tissue-Tek VIP). Specimens were embedded in paraffin, sectioned at 7 μm, and stained with Masson's trichrome stain (69) .
Electron microscopy. Mice were transcardially perfusion-fixed with 4% paraformaldehyde and 0.25% glutaraldehyde fixative in HEPES buffer. Whole muscles were dissected, diced into 1-2 mm 3 cubes, and further fixed with 4% glutaraldehyde in 0.1M cacodylate buffer for at least an hour. They were washed in 0.1M cacodylate buffer containing 7.5% sucrose, 3 X 20 min each wash. Specimens were then post-fixed in 1% osmium tetroxide in cacodylate buffer, dehydrated through a graded series of ethanol, followed by propylene oxide, and embedded in PolyBed 812 epoxy resin (Polysciences).
Specimens were baked overnight at 60 ºC. Semi-thin sections (0.5 μm) were cut and stained with toluidine blue. Ultra-thin sections (60-90 nm) were cut with a diamond knife and post-stained with uranyl acetate and lead citrate. Sections were examined in a Philips EM 400 or CM 12 electron microscope. Evans blue dye uptake assay. Mice were administered an intraperitoneal injection of EBD (Sigma) (1 mg/10 g body weight). After 16-18 hours, mice were euthanized and skinned. Whole limbs were fixed in 4% paraformaldehyde for 6 hours and examined macroscopically for dye uptake. For microscopic analysis, fresh quadriceps muscles were embedded in OCT over liquid nitrogen-cooled isopentane. 7 μm sections were cut and examined for dye uptake by fluorescence microscopy using a rhodamine filter.
Muscle physiology. EDL and soleus muscles were isolated, and the nerves to the muscles were dissected and cut. Ties were placed around the proximal and distal tendons of the muscle, and the muscle was removed. The tissue was placed in buffered mammalian Ringer's solution. The solution was maintained at 25 °C and gassed continuously with a mixture of 95% O 2 and 5% CO 2 . One tendon was tied to a servomotor (Aurora Scientific Inc.) and the other to a force transducer (Kulite model BG-50).
The muscle was stimulated directly by an electrical field generated between two large platinum electrodes situated in the bath on either side of the muscle. Square-wave pulses 0.2 ms in duration were amplified to increase current intensity to a sufficient level to produce a maximum response. Muscle length was adjusted for maximum isometric twitch force. The entire diaphragm, including adjacent ribs, was also removed and immersed in an oxygenated bath containing mammalian Ringer solution at 25 °C.
Diaphragm strips, 1-2 mm wide, were carefully dissected from the central region of the lateral costal hemi-diaphragm. The connections of the strip of fibers to a small section of a single rib and part of the central tendon were preserved. The rib and the tendon were attached to the force transducer and servo-motor. Diaphragm strips were stimulated directly by an electric field as described for EDL and soleus. To measure force deficits following lengthening contractions, two stretches of magnitude 0.3 fiber-lengths and velocity 0.5 fiber-lengths/s were initiated from the plateau of an isometric contraction.
Lengthening ramps were separated by 10 s and stimulation was terminated at the end of the second lengthening ramp. Force deficit was assessed during a final isometric tetanic contraction one minute after the second lengthening contraction ended. Further details on these physiological protocols can be found elsewhere (70) (71) (72) (73) . The maximum force generated by whole EDL muscles from TgT57I 
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